Study of experimental drug BP2202 for returning or resistant myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests an experimental drug called BP2202 for people with multiple myeloma that has returned or stopped responding to treatment. The goal is to see if it's safe and tolerable, and how it affects your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back or didn't respond to treatment.
- You are able to care for yourself and do light activities (ECOG 0 or 1).
- Your organs (like liver and kidneys) are working well enough.
- You have a measurable level of myeloma protein in your blood or urine.
- Your cancer has not spread to the brain or spinal cord.
- You don't have another cancer that is growing or needs treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (belantamab mafodotin, cevostamab, and pomalidomide) for patients with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if this combination is safe and effective.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This study tests a new drug, BMS-986453, for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if it is safe and works against the cancer.
This Phase 1 trial tests a new drug called RO7851624 in patients whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to understand how safe and effective this drug is.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
Hear when a new Relapsed/Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.